1800 244 735

Helpline (02) 9874 9777

Therapeutics conference videos now online

HDBuzz covered CHDI’s therapeutics conference in February 2011 from Palm Springs. Now, videos of many of the scientific presentations have been made available to watch online.

The therapeutics conference

The annual Huntington’s disease Therapeutics Conference, hosted by CHDI Foundation Inc., is a unique forum for HD researchers to come together, share exciting findings, and establish collaborations and partnerships that accelerate the pace of research into therapies for Huntington’s disease.

CHDI is a not-for-profit ‘virtual biotechnology company’ that aims to “rapidly discover and develop drugs that delay or slow Huntington’s Disease”. It’s the largest single driving force behind the development HD treatments.

Shortly after HDBuzz launched in January, we reported from the 2011 Therapeutics Conference, held in Palm Springs, California. Our daily reports from the conference gave a plain-language overview of all the main science presented at the conference – and it was a ton of exciting stuff!

You can find our reports by searching for ‘CHDI’ on HDBuzz.net.

The videos

For the first time, videos of many of the scientific presentations have now been made available online. To find them, visit http://chdifoundation.org/ and click the ‘Presentations from the 2011 HD Therapeutics Conference’ link.

Be prepared, though: these presentations were delivered by scientists, to a room full of scientists – so they’re all rather more intensive than a typical HDBuzz article!

So, you might find helpful to consult our daily conference reports, alongside the videos.

We applaud this move – it was an exciting conference and the science deserves to reach as many people as possible. As far as HDBuzz is concerned, making conference presentations available online like this is a great step forward.

Share on facebook
Share on twitter
Share on pinterest
Share on email

Latest Research Articles

Updates from the EHDN Plenary Meeting 2020

Published date: 8 January, 2021

In September, the European Huntington’s Disease Network (EHDN) hosted a virtual webinar event which comprised presentations on some of the latest scientific research as well as clinical studies of Huntington’s disease (HD). Researchers, doctors, patients and other interested folks, tuned in for an afternoon of talks as well as question and answer sessions to learn ... Read more

Uncovering the dark side of DNA repair to design HD treatments

Published date: 22 December, 2020

A gene known as ‘MSH3’, which encodes a protein involved in fixing and maintaining our DNA, has become a hot topic in Huntington’s research since being implicated as a key driver of the disease by multiple genetic studies. In a recent publication, a team of scientists from the National University of Ireland, Galway, have provided ... Read more

Huntington Study Group (HSG) 2020 Annual Conference: HD in Focus – Day 2

Published date: 1 November, 2020

The second day of the HSG conference was another busy day of presentations from HD researchers and clinicians. The day kicked off with a talk from Vaccinex who gave us an overview of their work on the SIGNAL clinical trial. Unfortunately, pepinemab, the medicine tested in this trial, did not influence HD symptoms and the ... Read more

Huntington Study Group (HSG) 2020 Annual Conference: HD in Focus – Day 1

Published date: 30 October, 2020

The Huntington Study Group (HSG) is a clinical research network focused exclusively on HD. Yesterday the HSG annual conference began with a schedule jam-packed with virtual talks from researchers, clinicians and different companies who are all working towards finding new medicines for HD. The day encompassed many interesting presentations which covered a lot of the ... Read more

Treatment for neurological disorder could be repurposed for Huntington’s disease patients

Published date: 22 October, 2020

While developing a drug called branaplam for patients with SMA, the pharmaceutical company Novartis discovered that it could hold promise for people with HD. The FDA has granted a special status called Orphan Drug Designation to branaplam. An existing drug…for huntingtin lowering? The pharmaceutical company Novartis has announced that the U.S. Food and Drug Administration ... Read more

Sad news from the SIGNAL study: pepinemab does not influence HD symptoms

Published date: 23 September, 2020

The SIGNAL clinical trial was designed to test a drug called pepinemab in people with early Huntington’s disease. The key results of that trial were recently announced, and unfortunately, pepinemab did not slow or improve HD symptoms as hoped. What was the SIGNAL trial, and who participated? The SIGNAL trial was launched in 2015 by ... Read more